ImmusanT
May 22, 2018
Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating
ImmusanT upgrading the management ahead of phase 2 celiac vaccine trial ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo’s SVP for internal medicine therapeutics, Ken Truitt, M.D., as its new chief medical officer. The management is also boosted with new VPs in program management and clinical oper...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
